How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

Improving Patient Assessment After Acute Kidney Injury (AKI)

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Health checks and monitoring — no treatment given
Type of study: Observational (no treatment given)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Iohexol renal clearance measurement (diagnostic test), Cystatin C (diagnostic test), Creatinine (diagnostic test), Semi structured interview (other)
How long the study runs: Study runs about 44 months (dates as stated)
About the drug or intervention: Iohexol renal clearance measurement — diagnostic test: Gold standard measurement of glomerular filtration rate. · Cystatin C — diagnostic test: Estimated GFR using serum cystatin C · Creatinine — diagnostic test: eGFR from serum creatinine level · Semi structured interview — other: Semi structured interview to explore patient experiences. · Participatory workshop — other: Group workshop using qualitative methods. · Metagenome analysis — diagnostic test: Analysis of the metagenome using faecal samples of participants after acute kidney injury · Bioimpedance analysis — diagnostic test: Estimation of body composition · Patient reported outcome measures — other: EQ-5D-5L, KSQ, WHO-DAS 2.0, K10 · Measurement of physical performance — other: Hand grip, Short physical performance battery
Patient visit burden: Not specified by the sponsor

Type of study: Observing health over time
Ages: 18 Years to 85 Years
Who: All
Number of participants: 100
Started: 2026-02-16
Last checked: 2025-12

Plain English Summary

What is this study?

• Testing a new treatment for acute kidney injury
• Clinical study - 100 participants
• The goal of this clinical trial is to improve patient care after acute kidney injury (AKI)

Who can take part?

• Ages 18 Years to 85 Years
• Diagnosed with acute kidney injury

Where?

• Derby - University Hospitals of Derby and Burton NHS Foundation Trust

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are: 1. Is creatinine or cystatin a more reliable assessment of kidney function after AKI? 2. What are the experiences of patients after AKI? 3. What interventions should be recommended to improve assessment and support of patients after AKI? Participants will be asked to do one or more of: * blood tests to measure kidney function in different ways * have measurement of their body composition * complete questionnaires about their symptoms * have an interview with a researcher about their experiences * discussion to develop an action plan based on findings

Acute Kidney Injury

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years - 85 Years
Who can join: All genders

What the study is looking for

✓Observational study workstream
✓Age 18-85 years
✓AKI stage 2 or 3 during hospital admission OR AKI stage 1 of at least 7 days duration during hospital admission
✓60-90 days after peak creatinine Qualitative interview workstream
✓AKI during hospital admission

Who cannot take part

✗Observational study workstream
✗Inability to give agreement to take part
✗No baseline creatinine available in previous 12 months
✗Pregnancy or breastfeeding
✗Current treatment with dialysis

See the full criteria

Inclusion Criteria: Observational study workstream * Age 18-85 years * AKI stage 2 or 3 during hospital admission OR AKI stage 1 of at least 7 days duration during hospital admission * 60-90 days after peak creatinine Qualitative interview workstream * Age 18-85 years * AKI during hospital admission * 60-90 days after peak creatinine Participatory workshop workstream * Age 18-85 years * Relevant experience (as assessed by the investigator) which could include personal experience of an episode of hospitalised AKI as a patient of carer, experience of managing AKI or related problems in a professional capacity or knowledge of a particular community. Exclusion Criteria: Observational study workstream * Inability to give informed consent * No baseline creatinine available in previous 12 months * Pregnancy or breastfeeding * Current treatment with dialysis * Renal transplant * Pacemaker in situ * Previous amputation * Allergy to Omnipaque contrast agent (WP1 only) * Manifest thyrotoxicosis (WP1 only) * Ascites or significant (grade 3 to 4) peripheral oedema, defined as ≥6 mm pit, lasting for \>1 minute after 5-second compression over tibia or medial malleolus (WP1 only) Qualitative interview workstream * Inability to give informed consent * No baseline creatinine available in previous 12 months * Current treatment with dialysis * Renal transplant * Receiving palliative care Participatory workshop workstream * Inability to give informed consent * Inability to communicate in English (the qualitative workshops will be held in English)

Where Is This Study? (1 UK site)

University Hospitals of Derby and Burton NHS Foundation Trust

Derby DE22 3DT, United Kingdom

Recruiting

Site contact (verified)

Kerry Horne Dr01332788262 kerry.horne@nottingham.ac.uk

How to Get in Touch

Kerry Horne Dr, BMBCh

Sponsor contact

CONTACT

+44 01332 788262 kerry.horne@nottingham.ac.uk

Data sourced from ClinicalTrials.gov · Last verified: 2025-12